KALRAY
5.7.2022 18:02:03 CEST | Business Wire | Press release
Clever Cloud , a European provider of automation and optimization solutions for websites and applications hosting, and Kalray (Paris:ALKAL) (Euronext Growth Paris: ALKAL), a leading provider of a new generation of processors and acceleration cards specialized in Intelligent Data Processing from Cloud to Edge, announce a partnership aimed at strengthening the relationship between the two companies for the deployment of next-generation storage solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220705005197/en/
Clever Cloud, which is currently setting up in a third Parisian data center and strengthening its technical platform, has chosen to partner with French company Kalray and its Flashbox™, a new generation of NVMe storage array that can accommodate up to 24 PCI Express (NVMe) SSDs, for its high-performance storage solution.
PERFORMANCE, RESILIENCE AND OPENNESS
Without a host CPU (Central Processing Unit), the Flashbox™ leverages K200-LP™ accelerator cards featuring the Coolidge™ DPU (Data Processing Unit) that takes advantage of the unique and patented MPPA® (Massively Parallel Processor Array) architecture developed by Kalray. This chip takes advantage of the power of 80 parallel cores and enables data centers adopting NVMe SSD storage to remove bottlenecks and improve performance, while consuming minimal power and resources.
A unique concept on the market today, the Flashbox™ as proposed by Kalray benefits from ultra-fast interfaces and low power consumption. It can deliver up to 12 million IOPS through a 2x 100 Gb/s network interface and is based on market standards such as Storage Performance Development Kit (SPDK), NVMe/TCP or RDMA over Converged Ethernet (RoCEv1/v2). It will eventually be offered by storage vendors using Kalray cards.
"Kalray's solution meets all our needs and the criteria that are important to us, whether in terms of sovereignty, openness, resilience, energy efficiency or performance ," said Quentin Adam, CEO of Clever Cloud.
The Flashbox™ is currently being tested in Clever Cloud's infrastructure and will join its new Paris data center where it will work alongside the latest generation of compute servers Clever Cloud is installing there. It will enable Clever Cloud to offer greater flexibility to its customers in managing storage, but also to support the launch of new offerings.
This is part of the development of Clever Cloud's Storage API, which allows various storage sources, whether local, remote or via third-party cloud service providers, to be simply allocated to the virtual machines that host users' applications. This open, multi-cloud approach is what makes Clever Cloud so successful.
CLEVER CLOUD AND KALRAY: FOR A “MADE IN FRANCE” R&D
Clever Cloud and Kalray are also partnering in several projects where they are working closely together to leverage Kalray's K200-LP™ cards as accelerators to offload Clever Cloud's network layer functionalities or computations related to the protection and redundancy of data stored within Clever Cloud's servers.
"The collaboration with Kalray is not just about two French companies that have an interest in working together, but about two projects that have, at their heart, the creation of value through innovation, where the partnership is also between the technical teams," adds Steven Le Roux, CTO of Clever Cloud .
“We are very pleased to be working with Clever Cloud, with whom we share common values, both in terms of innovation and the philosophy of our solutions, which are designed to be easy to use, flexible, scalable and open.
Kalray has a unique position in Europe in this market of very high-performance and low-power processors. We are proud to be able to build innovative French storage solutions with Clever Cloud and thus contribute to the technological sovereignty of France and Europe” , declares Eric Baissus, President and CEO of Kalray .
The Flashbox™ will be showcased at the upcoming Flash Memory Summit, a major event in the field, from August 2 to 4, 2022, in Santa Clara Convention Center, CA, USA (booth #940).
ABOUT CLEVER CLOUD
Founded in 2010, Clever Cloud is a company based in Nantes, France, and specialized in IT automation. It creates and provides the software building blocks necessary for the flexible deployment of applications on self-service PaaS architectures. Its clients include such major names as Airbus, AXA, Caisse d'Épargne, Cegid, Docaposte, MAIF, McDonald's, Solocal, SNCF, TBWA...
Website: https://www.clever-cloud.com
Latest news: https://www.clever-cloud.com/blog
ABOUT KALRAY
Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is a fabless semiconductor company, a leading provider of a new class of processors, specialized in Intelligent Data Processing from Cloud to Edge. Kalray’s team have created and developed its leading-edge technology and products to help its clients maximize the market possibilities presented by a world dominated by massive, disparate and pervasive data.
Thanks to Kalray’s patented manycore architecture, Kalray’s MPPA® Intelligent Data Processors are natively capable of managing multiple workloads with no bottlenecks to enable smarter, more efficient and energy-wise data-intensive applications. Kalray's offering includes processors, acceleration cards with associated software environment and appliances, allowing its customers to design the best solutions in fast growing sectors such as modern data centers, 5G, AI and Edge Computing, autonomous vehicles and others.
Founded in 2008 as a spin-off of CEA French lab, with investors such as Alliance Venture (Renault-Nissan-Mitsubishi), Safran, NXP Semiconductors, CEA and Bpifrance, Kalray is dedicated through technology, expertise and passion to offer more: More for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005197/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom